Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
Teva Pharmaceutical announced that Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, is departing the company. Dr. David Gardiner will serve as interim transition lead for R&D reporting to CEO Richard Francis. Despite the leadership change, Teva reaffirmed that its R&D strategy, priorities, and growth targets remain unchanged, including its ambition to generate $6-7 billion in innovative medicines revenue by 2030.
